Document is current
Any future updates will be listed below
-
Authors
Wilk, Aaron J. https://orcid.org/0000-0003-1430-5852
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Holmes, Susan
Blish, Catherine A. https://orcid.org/0000-0001-6946-7627
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM007365-44)
Stanford University
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 28020510, 1U2CCA23319501)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (1DP1DA053731, DP1 DA04508902)
Bill and Melinda Gates Foundation (INV-027498, OPP1202327)
MIT Stem Cell Initiative
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI161803)
- License Information
-
More Information
Article History
Received: 28 March 2022
Accepted: 5 April 2023
First Online: 11 May 2023
Competing interests
: A.K.S. reports compensation for consulting and/or scientific advisory board (SAB) membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ochre Bio, Third Rock Ventures, Hovione, Relation Therapeutics, FL82, Empress Therapeutics, IntrECate Biotherapeutics, Senda Biosciences and Dahlia Biosciences. C.A.B. reports compensation for consulting and/or SAB membership from Catamaran Bio, DeepCell, Immunebridge and Revelation Biosciences. The remaining authors declare no competing interests.
